首页 > 市场调查报告书 > 製药

眼科药物

市场调查报告书

商品编码

1358082

病毒性结膜炎治疗药物市场：依药物类别、按病毒类型、按配销通路、按地区

Viral Conjunctivitis Drugs Market, By Drug Class, By Virus Type (Adenovirus, Enterovirus, Others ), By Distribution Channel, By Geography

出版日期: 2023年08月31日 | 出版商:

Coherent Market Insights | 英文 214 Pages | 商品交期: 2-3个工作天内

价格

简介目录

预计2023年，全球病毒性结膜炎治疗药物市值为3.225亿美元，预计在预测期内（2023-2030年）年复合成长率为5.1%。

报告范围		报告详情
基准年	2022年	2023年市场规模	3.225 亿美元
实绩资料	2018-2021	预测期	2023-2030
预测期年复合成长率	5.10%	2030年市场规模预测	4.567 亿美元

2023 年按药物类别分類的病毒性结膜炎治疗药物的全球市场占有率（%）

病毒性结膜炎是由多种病毒引起的急性结膜感染疾病，包括腺病毒和单纯疱疹病毒。病毒性结膜炎占感染性结膜炎的大部分，占病例的75%。病毒性结膜炎的特征包括发红、红血管、眼睛分泌物、疼痛和畏光。由腺病毒群引起的病毒性结膜炎称为流行性角结膜炎（EKC）。这群腺病毒有不同的血清型，也可能引起咽结膜热和特异性滤泡性结膜炎。根据《美国眼科学会：2021》发表的一篇论文，腺病毒性结膜炎是成年人中最常见的眼部感染疾病类型。腺病毒结膜炎具有高度传染性，引起感染的病毒可以在檯面和其他表面上存活数週。

市场动态

市场参与者正在进行各种无机活动，例如公司收购、产品核可和其他活动，预计这些活动将在预测期内推动全球病毒性结膜炎治疗药物市场的成长。例如，2020 年 2 月，Bausch Health Companies Inc. 和製药公司的全资子公司 Eton Pharmaceuticals, Inc. 宣布已获得 Eton Pharmaceuticals 在临床实验滴眼剂 EM-100 的美国权利。如果核准，该滴眼剂将成为第一种用于治疗与结膜炎相关的眼睛搔痒的非处方（OTC）不含防腐剂的滴眼剂。

此外，2020年7月，全球眼科护理领导者爱尔康宣布，Pataday Once Daily Relief Extra Strength（盐酸奥洛他定眼用溶液0.7%）（原处方为Pazeo）已获得美国食品药物管理局批准，作为过度治疗药物。美国非处方药（FDA）宣布已获核准。 Pataday Once Daily Relief Extra Strength 是第一个也是唯一一个每天一次的滴眼液，无需处方笺即可提供 24 小时缓解眼睛瘙痒的效果。过敏是美国慢性病的第六大原因，非处方药零售额约 27 亿美元。

本研究的主要特点

该报告对全球病毒性结膜炎治疗药物市场进行了详细分析，并提供了以2022年为基准年的预测期（2023-2030年）的市场规模和年复合成长率(CAGR)。它揭示了各个细分市场的潜在商机，并说明了市场有吸引力的投资提案矩阵。
它还提供了有关市场促进因素、抑制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要考察。
它根据公司亮点、产品系列、主要亮点、绩效和策略等参数，介绍了全球病毒性结膜炎治疗药物市场的主要企业。
该报告的见解使行销人员和公司负责人能够就未来的产品发布、升级、市场扩张和行销策略做出明智的资讯。
全球病毒性结膜炎治疗药物市场报告迎合了该行业的各个相关人员，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
相关人员可以透过用于分析全球病毒性结膜炎治疗药物市场的各种策略矩阵来促进决策。

公司简介
- AbbVie Inc.
- Takeda Pharmaceutical Company Limited
- Bausch Health Companies Inc.
- Panoptes Pharma Ges.mbH
- NovaBay Pharmaceuticals, Inc.
- Nicox, NanoViricides Inc.
- Novartis International AG
- Pfizer Inc.
- Johnson &Johnson
- GlaxoSmithKline Plc.
- Santen Pharmaceutical Co.Ltd.
- Alcon
- Okogen Inc.

第10章章

参考
调查方法

简介目录

Product Code: CMI1281

The global viral conjunctivitis drugs market is estimated to be valued at US$ 322.5 million in 2023 and is expected to exhibit a CAGR of 5.1% during the forecast period (2023-2030).

Report Coverage		Report Details
Base Year:	2022	Market Size in 2023:	US$ 322.5 Mn
Historical Data for:	2018 to 2021	Forecast Period:	2023 - 2030
Forecast Period 2023 to 2030 CAGR:	5.10%	2030 Value Projection:	US$ 456.7 Mn

Global Viral Conjunctivitis Drugs Market Share (%), By Drug Class, 2023

Viral Conjunctivitis Drugs Market - IMG1

Viral conjunctivitis is an acute conjunctival infection that is caused by various viruses, such adenovirus, herpes simplex virus, etc. Viral conjunctivitis is responsible for the majority of infectious conjunctivitis, accounting for up to 75% of cases. Characteristics of ocular viral conjunctivitis include redness, blood vessel engorgement, ocular discharge, pain, photophobia, etc. Viral conjunctivitis that is caused by a group of adenoviruses is called epidemic keratoconjunctivitis (EKC). This family of adenoviruses contains different serotypes that can cause pharyngoconjunctival fever and nonspecific follicular conjunctivitis as well. According to the article published in the American Academy of Ophthalmology: 2021, adenoviral conjunctivitis is the most common type of eye infection in the adult population. Adenoviral conjunctivitis is highly contagious, as the virus causing the infection can survive on a countertop or a similar surface for several weeks.

Market Dynamics

Market players are engaged in various inorganic activities such as acquisitions of companies, product approval, and others, which in turn is expected to drive growth of the global viral conjunctivitis drugs market over the forecast period. For instance, on February 2020, Bausch Health Companies Inc.'s wholly owned subsidiary, Eton Pharmaceuticals, Inc., a pharmaceutical company, announced that they had acquired the U.S. rights to Eton Pharmaceuticals' EM-100, an investigational eye drop that, if approved, would be the first over-the-counter (OTC) preservative-free formulation eye drop to be used for the treatment of ocular itching associated with conjunctivitis.

Furthermore, in July 2020, Alcon, the global leader in eye care, announced that Pataday Once Daily Relief Extra Strength (olopatadine hydrochloride ophthalmic solution 0.7%), formerly prescribed as Pazeo, had been approved by the U.S. Food and Drug Administration (FDA) for sale over-the-counter (OTC) in the U.S. Pataday Once Daily Relief Extra Strength is the first and only once-daily eye allergy itch drop offering a full 24 hours of relief without a prescription. Allergies are the sixth-leading cause of chronic illness in the U.S., generating approximately US$ 2.7 billion in OTC retail sales.

Key features of the study:

This report provides an in-depth analysis of the global viral conjunctivitis drugs market and provides market size (US$ Million) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global viral conjunctivitis drugs market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include AbbVie Inc., Takeda Pharmaceutical Company Limited, Bausch Health Companies Inc., Panoptes Pharma Ges.m.b.H, NovaBay Pharmaceuticals, Inc., Nicox, NanoViricides Inc., Novartis International AG, Pfizer Inc., Johnson & Johnson, GlaxoSmithKline Plc., Santen Pharmaceutical Co.Ltd., Alcon and Okogen Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global viral conjunctivitis drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global viral conjunctivitis drugs market.

Detailed Segmentation:

By Drug Class:
- Antibiotics
- Artificial tears
- Decongestants
- Anti-histamines
- NSAIDS
- Anti-Viral drugs
- Others (Steroids, etc.)
By Viral Type:
- Adenovirus
- Enterovirus
- Others (Herpes Simplex Virus (HSV), etc.)
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
Company Profiles
- AbbVie Inc.
- Takeda Pharmaceutical Company Limited
- Bausch Health Companies Inc.
- Panoptes Pharma Ges.m.b.H
- NovaBay Pharmaceuticals, Inc.
- Nicox, NanoViricides Inc.
- Novartis International AG
- Pfizer Inc.
- Johnson & Johnson
- GlaxoSmithKline Plc.
- Santen Pharmaceutical Co.Ltd.
- Alcon
- Okogen Inc.

1. Research Objective and Assumption

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Virus Type
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Recent Test Launches
Epidemiology
Merger, Acquisition, and Collaborations
Regulatory Scenario
Key Developments
PEST Analysis

4. Global Viral Conjunctivitis Drugs Market - COVID-19 Impact Analysis

Economic Impact
COVID-19 Epidemiology
Impact on Supply and Demand

5. Global Viral Conjunctivitis Drugs Market, By Drug Class, 2018-2030, (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Antibiotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
Artificial tears
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
Decongestants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
Anti-histamines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
NSAIDS
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
Anti-Viral drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 -2030, (US$ Mn)
- Segment Trends

6. Global Viral Conjunctivitis Drugs Market, By Virus Type, 2018 - 2030, (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Adenovirus
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Segment Trends
Enterovirus
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Segment Trends
Others (Herpes Simplex Virus (HSV), etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Segment Trends

7. Global Viral Conjunctivitis Drugs Market, By Distribution Channel, 2018 - 2030, (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)

8. Global Viral Conjunctivitis Drugs Market, By Region, 2018-2030, (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
North America
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Virus Type, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018-2030, (US$ Mn)
U.S.
Canada
Europe
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Virus Type, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018-2030, (US$ Mn)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Virus Type, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018-2030, (US$ Mn)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Virus Type, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018-2030, (US$ Mn)
Brazil
Mexico
Argentina
Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2018 -2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Virus Type, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018-2030, (US$ Mn)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Virus Type, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country/ Region, 2018-2030, (US$ Mn)
North Africa
Central Africa
South Africa